Refine by
Oncology Articles & Analysis: Older
819 news found
RTsafe, a leading medical technology company specialising in quality assurance (QA) solutions for radiation therapy, and Icon Group (Icon), a leading integrated cancer care provider with a global reach across Australia, New Zealand, ASEAN, Mainland China and the United Kingdom, today announced the purchase of two RTsafe PRIME phantoms. These are the first PRIME phantoms to be installed in ...
ByRTsafe
An international survey from Ferring, Fertility Matters at Work and This Can Happen reveals a significant gap exists between employees and employers in recognising the experience of undergoing fertility treatment1 Nearly all employees say fertility treatment impacts their mental health, yet only one third feel supported by their employer’s fertility policies1 Around the world, ...
The controversial subject of fighting cancer is no longer limited to chemotherapy and radiation, and vaccines, once a word tied almost exclusively to infections, are now headline players in oncology. As reported by UCLA Health, a novel cancer vaccine could trigger robust immune responses in patients with pancreatic and colorectal cancer, driving a growing wave of research ...
” Creative BioMart remains committed to offering scientifically robust services that support advancements in immunology, oncology, infectious disease research, and biotherapeutic development. ...
Following the generation of successful results with the University of Michigan through the ACE program, Predictive Oncology is now actively calling for submissions for a new cohort of compounds to be tested in Q4 2025. ...
Medical science is witnessing remarkable advancements in neurology and oncology, with cutting-edge technologies shaping the future of patient care. ...
Cristofanilli, Director of Breast Medical Oncology and Scientific Director of EIPM at Weill Cornell Medicine. The See.d instrument and SmartBioSurface® slides are for Research Use Only and are not intended for use in diagnostic procedures. ...
Understanding that different therapeutic areas have unique challenges, the company adapts its services to cater to fields like oncology, neurology, and cardiology, among others. This flexibility ensures that their technology answers the specific needs of each research project, providing bespoke solutions that align with distinct research goals. ...
The addition of these new applications will help us gain a better understanding of what drives cancers down to a molecular level,” said Thomas Stricker, MD, PhD, Pathology Lab Director, Center for Molecular and Genomic Studies, Tennessee Oncology. The laboratory at Tennessee Oncology will streamline multiple NGS tests within one end-to-end workflow, ...
This technique combines the selectivity of antibodies with the potency of cytotoxic drugs, allowing for a highly focused approach to disease management, especially in oncology research. Additionally, CD Formulation offers Peptide Drug Conjugates (PDCs) service, which utilize homing peptides to streamline drug delivery to overexpressed protein receptors on tumor cells. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence company, to support better, data-driven outcomes in the rare disease and oncology fields. The two companies have expanded the integration of Genomenon’s ...
By facilitating the development of cutting-edge therapies, our products support advancements in various medical fields, including gene therapy, vaccine creation, and oncology treatments. “At Biopharma PEG, we are dedicated to providing innovative, high-performance PEG products tailored for the pharmaceutical and biotech sectors,” stated Brenda, Business Development ...
“Our collaboration with AstraZeneca represents a major step forward in personalized oncology. Non-small cell lung cancer remains one of the most challenging cancers to treat due to its complex biology and the late stage at which it is often diagnosed,” said Jurgi Camblong, Ph.D., Co-founder and CEO of SOPHiA GENETICS. ...
These institutions include renowned cancer centers and reference laboratories such as: BioReference® and Tennessee Oncology in the U.S.; Oncohelix in Canada; Dasa in Brazil; Universitätsklinikum Heidelberg in Germany; Stavanger University Hospital in Norway; IUCT Oncopole in France; Synnovis and South West Genomic Laboratory Hub, operating out of North Bristol NHS Trust ...
SOPHiA GENETICS offers a comprehensive suite of liquid biopsy applications that have helped progress oncology research and tumor mutation profiling. Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA (ctDNA). ...
The company has served the research and development needs of various fields, including neuroscience, oncology, and ...
FOLR1 testing is recommended for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.1 “Expanding our offerings to include tests for specific, predictive biomarkers, like HER2, can help reveal a patient’s responsiveness to therapies that have the potential to positively impact their outcome,” said Ezra Cohen, MD, Chief Medical Officer of ...
ByTempus
The magnitude and frequency of updates to oncology guidelines each year make it difficult for the updates to be rapidly incorporated into patient treatment plans. ...
ByTempus
Hazard Ratio of 9.69 vs. 2.13) In late 2023, Tempus formed a strategic collaboration with Personalis, Inc., a leader in advanced genomics for precision oncology, to co-commercialize NeXT Personal® Dx, an ultra-sensitive, tumor-informed MRD and monitoring test based on whole genome sequencing offered by Personalis. ...
ByTempus
Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur – Oncovita laboratory is to design and develop vaccine candidates through to proof of concept in humans. ...
ByOncoVITA